Cipla Ltd

Basis of our Recommendation

Cipla Ltd is currently navigating a challenging landscape characterized by near-term earnings pressure, particularly in its US segment, which has seen a sharp revenue decline. However, management remains optimistic about a recovery in the second half of FY27, driven by strategic product launches in the respiratory and peptide segments. The company's strong performance in the Indian market, particularly in chronic therapies, is a key growth driver, supported by a robust balance sheet and significant cash reserves for potential M&A. Despite facing margin pressures and regulatory risks, Cipla's focus on high-value product launches and expanding its biosimilar portfolio positions it well for future growth. Vista's forecast reflects a cautious outlook, anticipating revenue contraction over the forecast period, with margins expected to stabilize around 18.5-20%. The overall sentiment in the Indian pharmaceutical sector remains cautiously optimistic, bolstered by improving pricing power and a favorable regulatory environment. Key opportunities include the successful launch of new products and market penetration in chronic therapies, while watchpoints include regulatory approval timelines and competitive pricing pressures in the US market